NASDAQ · HOTH
Healthcare · Biotechnology
$1.36
Down-$0.02 (-2.22%)
Updated Aug 14, 2026, 11:07 PM
SID Score
6.3/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 0 trading sessions · Daily adjusted prices
HOTH does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
The latest Smart Investors Daily articles mentioning HOTH.
HOTH research
Company profile and research snapshot.
Hoth Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing new-generation therapies for unmet medical needs. It is focused on developing a topical formulation for treating side effects from drugs used for the treatment of cancer (HT-001); a treatment for mast-cell derived cancers and anaphylaxis (HT-KIT); and a treatment and/or prevention for Alzheimer's or other neuroinflammatory diseases (HT-ALZ). The company also has assets being developed for atopic dermatitis (also known as eczema) (BioLexa); a treatment for asthma and allergies using inhalational administration (HT-004); and an obesity treatment, and obesity-related diseases and conditions (HT-VA).
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Mar 25, 2026 | D. Boral Capital | Buy | — |
| Mar 4, 2026 | D. Boral Capital | Buy | — |
| Dec 4, 2025 | D. Boral Capital | Buy | — |
| Nov 17, 2025 | D. Boral Capital | Buy | — |
| Aug 18, 2025 | D. Boral Capital | Buy | — |
No generated briefing is available yet.
Benzinga · Mar 4, 2026
The OpenAI-powered API platform has been integrated into the HT-KIT development workflow to support preclinical data analysis, molecular modeling of KIT-driven pathways, and preparation of regulatory documentation ahead
Benzinga · Feb 24, 2026
CLEER-001 Phase 2a Expansion Signals Growing Momentum Behind First-in-Class Therapy for Cancer Patients With No Current FDA-Approved Treatment OptionNEW YORK, Feb. 24, 2026 /PRNewswire/ -- Hoth Therapeutics, Inc.
Benzinga · Feb 10, 2026
Hoth Therapeutics shared early study data showing its obesity drug candidate outperformed semaglutide on weight, glucose control, and liver health, with stronger effects seen in female models.
Benzinga · Feb 10, 2026
Key Study Highlights: Superior Weight Management: In female mice on a high-fat Western diet, GDNF attenuated weight gain by 10-15%, leading to a plateau in the final weeks of treatment—unlike semaglutide, which showed
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning HOTH.
